Clinical Trial Update: The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the minimum effective dose (ED90) of liposomal bupivacaine for preserving motor function in motion sickness has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Motion Sickness

Drugs mentioned

• Exparel (liposomal bupivacaine) (liposomal bupivacaine)

Snippet

Sponsor: Affiliated Hospital of Jiaxing University | Conditions: Motion Sickness | Phase 4 | Status: COMPLETED